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Recent studies involving animal models of cancer and clinicopathological analyses of human tumours suggest that the growth of
lymphatic vessels (lymphangiogenesis) in or nearby tumours is associated with the metastatic spread of cancer. The best validated
molecular signalling system for tumour lymphangiogenesis involves the secreted proteins vascular endothelial growth factor-C (VEGF-
C) and VEGF-D that induce growth of lymphatic vessels via activation of VEGF receptor-3 (VEGFR-3) localised on the surface of
lymphatic endothelial cells. In this review, we discuss the evidence supporting a role for this signalling system in the spread of cancer
and potential approaches for blocking this system to prevent tumour metastasis.
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The lymphatic vasculature is an important route for the metastatic
spread of human cancer. Hence, in almost all carcinomas, the
presence of tumour foci in lymph nodes is the most important
adverse prognostic factor in apparently localised disease. Further-
more, inhibition of regional lymph nodal metastasis was associated
with reduced distant organ metastasis in some animal models
suggesting a pathway may exist for distant organ metastasis via the
lymph nodes (e.g. see Krishnan et al, 2003). It was previously
thought that lymphatic metastasis involved passage of malignant
cells along pre-existing lymphatic vessels near a tumour, however,
recent studies in animal models suggest that lymphangiogenesis
can be induced by solid tumours and may promote tumour spread
(for a review see Saharinen et al, 2004). Moreover, clinicopatho-
logical studies have revealed that lymphangiogenesis can occur
adjacent to or within human cancers and that this correlates with
metastasis to lymph nodes in some tumour types including head
and neck cancer (Beasley et al, 2002) and cutaneous melanoma
(Dadras et al, 2003) (Table 1). The location of tumour lymphatics
may be an important issue for metastatic spread as some studies
have indicated that intratumoural lymphatic vessels are nonfunc-
tional and that peritumoural lymphatics are more important for
this process (e.g. see Padera et al, 2002). The extensive
experimental and clinicopathological studies of tumour lymphan-
giogenesis carried out over the past 5 years suggest that it may be a
useful target for therapeutics designed to restrict cancer meta-
stasis.
The best validated signalling system for tumour lymphangio-
genesis involves the secreted glycoproteins VEGF-C and VEGF-D
that signal via VEGF receptor-3 (VEGFR-3; also known as Flt4),
expressed on the surface of lymphatic endothelial cells (Joukov
et al, 1996; Achen et al, 1998; Veikkola et al, 2001). Vascular
endothelial growth factor-C and VEGF-D have been shown to
promote tumour lymphangiogenesis, the metastatic spread of
tumour cells to lymph nodes and, in some cases, distant organ
metastasis in multiple animal models of cancer (for a review see
Saharinen et al, 2004). Furthermore, expression of these growth
factors appears to correlate with lymph node metastasis in
numerous common human cancers (for a review see Stacker
et al, 2002a). Other protein growth factors that have also been
implicated in tumour lymphangiogenesis are platelet-derived
growth factors (PDGFs) (Cao et al, 2004) and VEGF-A (Hirakawa
et al, 2005), however, the evidence for involvement of these
molecules in tumour lymphangiogenesis is currently restricted to
relatively few animal models and therefore requires analysis in a
broader range of experimental models as well as extensive
clinicopathological studies to correlate the expression of these
molecules with metastasis in human cancer. In summary, the
VEGF-C/VEGF-D/VEGFR-3 signalling system is currently the most
attractive target for antilymphangiogenic therapeutics designed to
restrict cancer metastasis, although it is likely that other validated
targets will emerge in future. We therefore focus on the VEGF-C/
VEGF-D/VEGFR-3 signalling system in this article.
VEGF-C/VEGF-D/VEGFR-3 SIGNALLING AND
TUMOUR METASTASIS
Mechanisms of lymphangiogenic signalling
The lymphangiogenic growth factors VEGF-C and VEGF-D are
synthesised as proproteins consisting of a central VEGF homology
domain (VHD), containing receptor-binding sites, flanked by N-
and C-terminal propeptides (Joukov et al, 1996; Achen et al, 1998).
Subsequently, the propeptides can be proteolytically removed to
generate mature forms consisting of VHD dimers. The full-length
forms of both growth factors bind the lymphangiogenic receptor
VEGFR-3 but the mature forms do so with greater affinity (Joukov
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proteolytic processing of VEGF-C and VEGF-D may in part
determine the extent of lymphangiogenesis induced by these
proteins in a tumour. Once VEGF-C is processed to the mature
form it acquires the capacity to bind VEGFR-2 (Joukov et al, 1997),
a cell surface receptor tyrosine kinase thought to signal for
angiogenesis. In the case of VEGF-D, the affinity for VEGFR-2 is
increased approximately 290-fold by proteolytic conversion of the
full-length to the mature form (Stacker et al, 1999). Hence the
mature forms of VEGF-C and VEGF-D can induce angiogenesis
(Cao et al, 1998; Rissanen et al, 2003). The enzymes known to
process VEGF-C or VEGF-D are the serine protease plasmin
(McColl et al, 2003) and members of proprotein convertase (PC)
family, namely furin, PC5 and PC7 (Siegfried et al, 2003). Plasmin
also cleaves some isoforms of the angiogenic growth factor VEGF-
A, releasing them from the extracellular matrix or cell surface thus
making them available for inducing angiogenesis (Houck et al,
1992). The PCs have also been implicated in activation of other
growth factors involved in lymphangiogenesis or angiogenesis,
such as PDGFs (Siegfried et al, 2005). Hence these proteases could
play a broad role in regulating growth of lymphatics and blood
vessels in cancer.
As is the case for receptor tyrosine kinases in general, activation
of VEGFR-3 by its ligands VEGF-C or VEGF-D results in trans-
phosphorylation of tyrosine residues in the cytoplasmic domains
of the dimerised receptor (Dixelius et al, 2003). Such phospho-
rylation events are known to be critical for the regulation of
receptor kinase activity and for receptor interactions with signal
transduction molecules. Analysis of VEGFR-3 signalling in
lymphatic endothelial cells in culture indicated that activation of
VEGFR-3 alone was sufficient to protect the cells from apoptosis
and to induce proliferation and migration (Makinen et al, 2001).
At least some of these signals were transduced by protein kinase C-
dependent activation of the p42/p44 MAPK signalling cascade and
via induction of Akt phosphorylation, two important signalling
systems known to be associated with cell growth and survival.
Further aspects of the VEGFR-3 signalling pathways remain to be
elucidated and may be more complex than originally thought given
that VEGFR-3 has been reported to form heterodimers with
VEGFR-2 (Dixelius et al, 2003).
Lymphangiogenic signalling and tumour metastasis
A range of experimental studies in animal models demonstrated
that the VEGF-C/VEGF-D/VEGFR-3 signalling axis can promote
tumour lymphangiogenesis and the metastatic spread of tumour
cells. One approach has involved expressing VEGF-C or VEGF-D
in tumour cells and monitoring the effects on lymphatic vessels
within or adjacent to solid tumours as well as assessing the degree
to which tumour cells spread to lymph nodes. For example,
expression of VEGF-C in breast cancer cells increased
intratumoural lymphangiogenesis and metastasis to lymph nodes
and lung after injection into mice (Skobe et al, 2001b). In other
models, expression of VEGF-C in breast cancer cells promoted
growth of tumour-associated lymphatics (Skobe et al, 2001a), that
were in some cases infiltrated with tumour cells (Karpanen et al,
2001), and metastatic spread to lymph nodes (Mattila et al, 2002).
In a transgenic mouse model of pancreatic cancer, expression of
VEGF-C in tumour cells led to extensive lymphangiogenesis
associated with the tumours and metastases in draining lymph
nodes (Mandriota et al, 2001). Expression of VEGF-D in tumour
cells of a mouse xenograft model promoted formation of
intratumoural lymphatics, angiogenesis, tumour growth and
metastasis to lymph nodes (Stacker et al, 2001). The lymphatic
metastasis in this model was prevented by a neutralising VEGF-D
antibody that blocked binding of this growth factor to both
VEGFR-2 and VEGFR-3 (Achen et al, 2000; Stacker et al, 2001).
Further, VEGF-D promoted tumour lymphangiogenesis and
lymphatic metastasis in mouse models of pancreatic cancer (Von
Marschall et al, 2005).
An alternative approach for assessing the role of the VEGF-C/
VEGF-D/VEGFR-3 system in cancer metastasis has been to treat
well-established animal models of tumour spread, that have not
been genetically engineered to express VEGF-C or VEGF-D, with
inhibitors of this signalling pathway and to monitor the effects on
lymphatic and distant organ metastases. For example, the highly
metastatic human lung cancer cell line NCI-H460-LNM35 was
transfected with an expression construct for a soluble version of
VEGFR-3 (soluble VEGFR-3) that binds VEGF-C and thereby
inhibits signalling by endogenous VEGFR-3 (He et al, 2002). The
resulting tumour xenografts in mice contained fewer intra-
tumoural lymphatic vessels and there were less metastases in
draining lymph nodes than for control tumours that did not
express soluble VEGFR-3. Mice with control NCI-H460-LNM35
tumours (i.e. not expressing soluble VEGFR-3) were treated with
recombinant adenovirus expressing soluble VEGFR-3 as an
alternative inhibitory strategy – this also restricted lymph node
metastasis (He et al, 2002). In another animal model, expression of
a soluble VEGFR-3 in highly metastatic MT-450 mammary tumour
cells suppressed metastasis formation both in the regional lymph
nodes and the lungs of rats (Krishnan et al, 2003). More recently, a
recombinant adeno-associated virus expressing a soluble VEGFR-3
was shown to inhibit lymph node metastasis in a melanoma model
in mice (Lin et al, 2005) and inhibition of VEGF-C expression
using small interfering RNA-mediated gene silencing reduced
lymphangiogenesis, lymph node metastasis and spontaneous lung
metastasis in a mouse mammary tumour model (Chen et al, 2005).
However, inhibition of tumour lymphangiogenesis using a soluble






Is lymph node metastasis correlated with
lymphangiogenesis? Reference
Head and neck cancer IT and PT Yes, with both IT and PT (Beasley et al, 2002; Franchi et al, 2004)
Colorectal cancer IT Yes, with IT (Kuroyama et al, 2005)
Cutaneous melanoma
b IT and PT Yes, with both IT and PT (Dadras et al, 2003)
Non-small-cell lung cancer Predominantly PT Yes, with PT (Renyi-Vamos et al, 2005)
Gastric cancer IT and PT Yes, but type of lymphangiogenesis correlated with metastasis
was not defined
(Nakamura et al, 2006)
Cancer of the uterine cervix IT and PT Yes, with PT only (Gombos et al, 2005)
Breast cancer
b PT No, lymph node metastasis correlated with tumour invasion of
lymphatics, not with lymphatic vessel density
(Schoppmann et al, 2004)
Papillary thyroid cancer IT (PT not analysed) Yes, with IT (Hall et al, 2003)
aIT denotes intratumoural and PT denotes peritumoural.
bThere has been at least one report disputing that lymphangiogenesis occurs in this tumour type.
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mouse model of prostate cancer suggesting that lymphangiogen-
esis is not an essential requirement for lymphatic spread in all
tumours (Wong et al, 2005).
Clinicopathological studies carried out over the past 7 years
have reported that expression of VEGF-C, VEGF-D or VEGFR-3
can correlate with lymph node metastasis in human cancer, a topic
that has been extensively reviewed in recent times (Stacker et al,
2002a,b; He et al, 2004). According to some of these studies,
VEGF-C expression in tumour cells correlates with lymph node
metastasis in lung, colorectal and prostate cancer (for review see
Stacker et al, 2004) and may be a prognostic factor in ovarian and
cervical cancer (Ueda et al, 2002; Nishida et al, 2004). Vascular
endothelial growth factor-D expression was reported to be
associated with lymphatic involvement and a prognostic marker
in colorectal cancer (White et al, 2002) and a predictor of poor
outcome in epithelial ovarian carcinoma (Yokoyama et al, 2003).
Interestingly, VEGF-D and VEGFR-3 were recently reported to be
independent prognostic markers in gastric adenocarcinoma and
the presence of VEGF-D was correlated with lymphatic metastases
in this tumour type (Juttner et al, 2006). There have been many
reports of human tumours in which tumour cells express
lymphangiogenic growth factors, but it is important to note that
tumour-associated inflammatory cells, such as macrophages, can
also express VEGF-C and VEGF-D, and could thereby play an




The approach for targeting the VEGF-C/VEGF-D/VEGFR-3 path-
way that has been most extensively employed in animal models of
cancer, but is yet to be tested in the clinic, is the use of soluble
versions of VEGFR-3 that bind VEGF-C and VEGF-D, thereby
inhibiting activation of endogenous VEGFR-3 (see previous
section) (He et al, 2002; Krishnan et al, 2003; Lin et al, 2005). It
is yet to be determined if a soluble VEGFR-3 construct binds
VEGF-C and VEGF-D so that these growth factors are also unable
to activate endogenous VEGFR-2 – if this were the case soluble
VEGFR-3 would have the merit of preventing the contribution
made by these growth factors to angiogenic signalling in cancer via
VEGFR-2 as well as lymphangiogenic signalling via VEGFR-3.
Soluble versions of cell surface receptors are already used in
clinical medicine, such as Enbrel
s (also known as etanercept), a
recombinant soluble version of the p75 receptor for tumour
necrosis factor, that is used to treat rheumatoid arthritis (for a
review see Maini and Taylor, 2000).
Other potential antilymphangiogenic therapeutics that would
not enter the cell includes monoclonal antibodies to VEGF-C and
VEGF-D, which block binding to both VEGFR-2 and VEGFR-3.
Such an antibody to VEGF-D has already been described (Achen
et al, 2000) and was shown to block angiogenesis, lymphangiogen-
esis and lymph node metastasis in a VEGF-D-dependent mouse
tumour model (Stacker et al, 2001). Monoclonal antibodies to
VEGFR-3 that block the binding of VEGF-C and VEGF-D could
also be effective. Such an antibody to VEGFR-3 has been shown to
block regeneration of adult lymphatic vessels (Pytowski et al, 2005)
but its effects in cancer have not been reported. This type of
reagent would not block activation of VEGFR-2 by VEGF-C or
VEGF-D, however, bispecific antibodies that bind both VEGFR-2
and VEGFR-3 (Jimenez et al, 2005) could possibly be used for this
purpose. Monoclonal antibodies are well established as anticancer
therapeutics, one example being an antibody to VEGF-A, known as
bevacizumab or Avastin
s, that is designed to restrict tumour
angiogenesis and used to treat patients with metastatic colorectal
cancer (Ferrara et al, 2004).
An alternative strategy to receptor constructs and antibodies
involves small molecules that enter the cell such as inhibitors of
the VEGFR-3 tyrosine kinase or of downstream signalling
molecules. A range of small molecules has been shown to inhibit
the VEGFR-3 kinase, in addition to multiple other kinases such as
VEGFR-2, some of which are in clinical trials as anticancer
therapeutics – these include BAY 43-9006, CEP-7055 and PTK787/
ZK 222584 (for a review see Achen et al, 2005). The signalling
mechanisms downstream of activated VEGFR-3 are inadequately
understood to justify targeting this component of lymphangio-
genic signalling at this stage.
How might an antimetastatic therapy, based on inhibiting
tumour lymphangiogenesis, be utilised in the clinic? The manage-
ment of most solid tumours involves surgical removal of the
primary cancer to achieve local disease control and to restrict
further metastatic spread. In cancers where effective systemic
therapies are available, patients with tumour characteristics
indicating there is a moderate to high risk of subsequent distant
relapse are offered adjuvant therapy (Sun and Haller, 2005). This is
usually in the form of cytotoxic chemotherapy, or some form of
endocrine manipulation. Recently there has been intense investi-
gation of the use of systemic therapies before surgery (Wolmark
et al, 2001). This has been widely used to reduce the size of the
primary cancer to facilitate surgery, for example by making a
borderline resectible tumour more easily resectible, or to allow
breast conservation for a tumour that would otherwise have
required a mastectomy (Wolmark et al, 2001). More recently, there
have been examples suggesting an improved cancer outcome with
a preoperative approach (Malthaner and Fenlon, 2003). An
antilymphangiogenic approach could be used in conjunction with
conventional chemotherapy regimens in these scenarios (Figure 1),
and may possibly reduce the incidence of local or distant
recurrence. Treatment of advanced, nonresectible cancer remains
inadequate in almost all cancers, and antilymphangiogenic agents
may have a role in combination with other systemic agents in this
scenario.
Several criteria should be met before introducing antilymphan-
giogenic agents to clinical trials. Reliable assays to detect the
presence of VEGF-C, VEGF-D and VEGFR-3, and also to detect
intra- or peritumoural lymphangiogenesis must be in place.
Approaches for detecting these by immunohistochemistry, includ-
ing identification of lymphatic vessels by staining for markers such
as LYVE-1 (Dadras et al, 2003) and podoplanin (Renyi-Vamos
et al, 2005), have been described in the clinicopathological
literature and may require further development to become
sufficiently robust. Initial trials should be performed on cancers
in which lymphangiogenesis can be detected in a reasonable
proportion of cases. Repeat biopsy and reassay after treatment is
also important for the purposes of trials. While initial trials may be
performed with patients with advanced disease, the neoadjuvant
setting may yield the best results. Further work on tissue-banked
specimens from breast, colorectal, esophago-gastric, lung and head
and neck cancer specimens may identify the best candidate
cancers, but ultimately it will require careful clinical trials with
biological as well as clinical end points to assess this approach.
CONCLUDING REMARKS
There is considerable experimental and clinicopathological evi-
dence suggesting that tumour lymphangiogenesis is associated
with the metastatic spread of cancer. Moreover, studies in
experimental models of cancer have demonstrated that the
VEGF-C/VEGF-D/VEGFR-3 signalling system is a key regulator
of tumour lymphangiogenesis. This is further supported by
clinicopathological analyses of human cancer showing that
expression of VEGF-C and VEGF-D can correlate with lymph
node metastasis in some human cancers. Numerous reagents that
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soluble VEGFR-3 protein constructs, neutralising monoclonal
antibodies to VEGFR-3 and VEGF-D, and small molecule
inhibitors of the VEGFR-3 kinase. Some of these reagents should
also block the contribution of VEGF-C and VEGF-D to tumour
angiogenesis via VEGFR-2, which could provide added benefit for
patients. Hence, it is now appropriate to test this approach in the
clinic. Some of the small molecule VEGFR-3 inhibitors are already
in clinical trials, however, these trials are not specifically designed
to monitor effects on metastasis. Indeed, clinical testing of an
antimetastatic approach to cancer may require new strategies for
trials so that the occurrence of cancer metastases can be
monitored. Nevertheless, clinical testing of this approach is
warranted in the near future.
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